Infectious Disease

Dialysis patients develop SARS-CoV-2 antibodies, which reduce the likelihood of reinfection

17th August 2021

Read for 1 minute

Source / information

Published by:

Disclosure:
The authors do not report any relevant financial information.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Hemodialysis patients who survived infection with SARS-CoV-2 developed and received antibodies that resulted in a lower likelihood of reinfection compared to previously uninfected patients.

“Serious infections with the acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have devastating effects on patients on hemodialysis. The extent to which infection-induced antibody reactions maintain or protect is not known. ” Gemma D. Banham, MRCP, from the College of Medical and Dental Sciences at the University of Birmingham, and colleagues wrote. “This study describes the development of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 hemodialysis patients.”

SARS-CoV-2 antibodies

The content of the infographic was adapted from Banham GD et al. J Am Soc Nephrol. 2021; doi: 10.1681 / ASN.2021020188.

During the first wave of the pandemic (defined as March to July 2020), researchers found that 26% of patients had developed SARS-CoV-2 antibodies to spikes, and 75.9% of those patients had developed antibody- a median 124 days after infection. stayed positive.

Researchers observed fewer PCR-confirmed infections in patients with pre-existing antibodies than in those without antibodies during the second wave (defined as October 2020 to January 2021) (4.2% vs. 11.4%, a risk ratio of 0.37) is equivalent to.

The antibody status did not distinguish whether patients were symptomatic, hospitalized, or died.

“In summary, hemodialysis patients who survive SARS-CoV-2 infection produce an antibody response that is well sustained and appears to be associated with a reduced frequency of reinfection,” wrote Banham and colleagues. “Because patients with lower responses may be at increased risk of reinfection, the ability of anti-vaccine antibody responses to protect patients on hemodialysis should be closely monitored to determine effectiveness.”

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles